JANSSEN RESEARCH & DEVELOPMENT, LLC

πŸ‡ΊπŸ‡ΈUnited States
Ownership
-
Employees
-
Market Cap
-
Website

Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

First Posted Date
2022-04-14
Last Posted Date
2024-12-06
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
201
Registration Number
NCT05327114
Locations
πŸ‡ΊπŸ‡Έ

Johns Hopkins Hospital, Baltimore, Maryland, United States

πŸ‡¨πŸ‡³

Chifeng Municipal Hospital, Chifeng, China

πŸ‡¨πŸ‡³

Peking University Third Hospital, Beijing, China

and more 68 locations

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

First Posted Date
2022-04-07
Last Posted Date
2024-12-05
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
112
Registration Number
NCT05316155
Locations
πŸ‡ΊπŸ‡Έ

University of Southern California, Los Angeles, California, United States

πŸ‡ΊπŸ‡Έ

Northwestern University, Chicago, Illinois, United States

πŸ‡ΊπŸ‡Έ

Urology San Antonio Research, San Antonio, Texas, United States

and more 18 locations

A Study of Seltorexant in Participants With Probable Alzheimer's Disease

Phase 2
Completed
Conditions
Interventions
First Posted Date
2022-04-01
Last Posted Date
2024-12-09
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
88
Registration Number
NCT05307692
Locations
πŸ‡ΊπŸ‡Έ

Allied Biomedical Research Institute (ABRI), Inc, Miami, Florida, United States

πŸ‡ΊπŸ‡Έ

Quantix Research, Miami, Florida, United States

πŸ‡ΊπŸ‡Έ

Entrust Clinical Research, Miami, Florida, United States

and more 22 locations

A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)

First Posted Date
2022-03-25
Last Posted Date
2023-05-09
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
3
Registration Number
NCT05295927
Locations
πŸ‡ΊπŸ‡Έ

GU Research Network, Omaha, Nebraska, United States

πŸ‡ΊπŸ‡Έ

Chesapeake Urology Research Associates, Towson, Maryland, United States

πŸ‡ΊπŸ‡Έ

Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States

and more 1 locations

An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B Participants

First Posted Date
2022-03-11
Last Posted Date
2024-12-06
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
37
Registration Number
NCT05275023
Locations
πŸ‡ͺπŸ‡Έ

Hosp. Univ. Pta. de Hierro Majadahonda, Madrid, Spain

πŸ‡¬πŸ‡§

Imperial College London and Imperial College Healthcare NHS Trust, London, United Kingdom

πŸ‡«πŸ‡·

Hopital Beaujon, Clichy, France

and more 23 locations

Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis

Phase 3
Active, not recruiting
Conditions
Interventions
First Posted Date
2022-03-09
Last Posted Date
2024-12-06
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
213
Registration Number
NCT05272150
Locations
πŸ‡ΊπŸ‡Έ

Austin Institute for Clinical Research, Pflugerville, Texas, United States

πŸ‡ΊπŸ‡Έ

Florida Academic Dermatology Centers, Coral Gables, Florida, United States

πŸ‡ΊπŸ‡Έ

Hollywood Dermatology and Cosmetic Surgery, Hollywood, Florida, United States

and more 89 locations

A Study to Assess Feasibility of Using Clinician-directed and Digital Application Supported Cognitive Behavior Therapy (CBT) in Conjunction With Esketamine in Participants With Treatment-resistant Depression

First Posted Date
2022-03-07
Last Posted Date
2022-09-22
Lead Sponsor
Janssen Research & Development, LLC
Registration Number
NCT05268497
Locations
πŸ‡ΊπŸ‡Έ

University of Chicago, Chicago, Illinois, United States

πŸ‡ΊπŸ‡Έ

Sheppard Pratt Health System, Baltimore, Maryland, United States

πŸ‡ΊπŸ‡Έ

Rush University Medical Center, Chicago, Illinois, United States

and more 2 locations

A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis

Phase 2
Recruiting
Conditions
Interventions
First Posted Date
2022-03-03
Last Posted Date
2024-12-10
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
12
Registration Number
NCT05265273
Locations
πŸ‡ΊπŸ‡Έ

Penn State Milton S Hershey Medical Ctr, Hershey, Pennsylvania, United States

πŸ‡ΊπŸ‡Έ

Phoenix Children's Hospital, Phoenix, Arizona, United States

πŸ‡ΊπŸ‡Έ

Childrens Hospital Los Angeles, Los Angeles, California, United States

and more 16 locations

A Study of JNJ-77474462 (Bermekimab) in Healthy Chinese Participants

Phase 1
Withdrawn
Conditions
Interventions
First Posted Date
2022-02-23
Last Posted Date
2023-01-27
Lead Sponsor
Janssen Research & Development, LLC
Registration Number
NCT05252520
Locations
πŸ‡¨πŸ‡³

Nanfang Hospital of Southern Medical Hospital, Guangzhou, China

A Study of Ustekinumab in Pediatric Participants (U-POPS) With Juvenile Psoriatic Arthritis or Psoriasis

First Posted Date
2022-02-23
Last Posted Date
2024-03-01
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
31
Registration Number
NCT05252533
Locations
πŸ‡ΊπŸ‡Έ

Northwestern University Feinberg School of Medicine Ann & Robert H Lurie Children's Hospital, Chicago, Illinois, United States

πŸ‡ΊπŸ‡Έ

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

πŸ‡ΊπŸ‡Έ

Newport Huntington Medical Group, Huntington Beach, California, United States

and more 7 locations
Β© Copyright 2024. All Rights Reserved by MedPath